PBPH.US Portfolio Building Block World Pharma and Biotech Index ETF
- Total assets
- 1.34B
- Expense ratio
- -
- Dividend yield
- -
- 1-year return
- -
- Holdings
- 52
- Since
- 2025
Fund data as reported by the issuer, updated Nov 15, 2026. Total assets are in the fund's base currency.
What does PBPH.US invest in?
- Mostly US stocks (69.9%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (70.0%)
- Top 3 holdings: 34.2% of the fund
Asset allocation
- US stocks 69.9%
- Non-US stocks 32.6%
- Cash 0.3%
Top holdings
- Eli Lilly and Company 16.82%
- Johnson & Johnson 10.14%
- AbbVie Inc 7.19%
- Merck & Company Inc 5.00%
- AstraZeneca PLC 4.92%
Portfolio Building Block World Pharma and Biotech Index ETF performance
Sharpe ratio 0.00- This year
- +24.88%
- 1 year
- -
- 3 years
- -
- 5 years
- -
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
PBPH.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Portfolio Building Block World Pharma and Biotech Index ETF
The fund uses a "passive management" approach to track the performance, before fees and expenses, of the index. The index is constructed using a rules-based methodology that identifies companies in the pharmaceutical and/or biotechnology industries with publicly traded ordinary shares listed on major stock exchanges in developed markets, as classified by BITA GmbH. Under normal circumstances, the fund will invest at least 80% of the fund"s net assets in component securities …
Full fund profilePortfolio Building Block World Pharma and Biotech Index ETF top holdings
64.7% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Eli Lilly and Company LLY.US | Healthcare | United States | 16.82% |
| Johnson & Johnson JNJ.US | Healthcare | United States | 10.14% |
| AbbVie Inc ABBV.US | Healthcare | United States | 7.19% |
| Merck & Company Inc MRK.US | Healthcare | United States | 5.00% |
| AstraZeneca PLC AZN.LSE | Healthcare | United Kingdom | 4.92% |
| Roche Holding AG ROP.SW | Healthcare | Switzerland | 4.73% |
| Amgen Inc AMGN.US | Healthcare | United States | 4.48% |
| Novartis AG NOVN.SW | Healthcare | Switzerland | 4.26% |
| Gilead Sciences Inc GILD.US | Healthcare | United States | 3.85% |
| Pfizer Inc PFE.US | Healthcare | United States | 3.29% |
The 10 largest of 52 holdings.
PBPH.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
PBPH.US regional exposure
- North America70.0%
- Europe Developed18.6%
- United Kingdom7.3%
- Japan3.9%
- Australasia1.3%
- Africa/Middle East1.0%
Share of the stocks in the fund.
Company size
Average market cap 234B- Mega cap41.7%
- Big cap48.0%
- Medium cap9.3%
- Small cap1.4%
Portfolio Building Block World Pharma and Biotech Index ETF fund profile
- Fund name
- Portfolio Building Block World Pharma and Biotech Index ETF
- Ticker
- PBPH.US
- Exchange
- USA Stocks
- Issuer
- Portfolio Building Block ETFs
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Nov 25, 2025
- Trading currency
- USD
- Expense ratio
- -
About Portfolio Building Block World Pharma and Biotech Index ETF
The fund uses a "passive management" approach to track the performance, before fees and expenses, of the index. The index is constructed using a rules-based methodology that identifies companies in the pharmaceutical and/or biotechnology industries with publicly traded ordinary shares listed on major stock exchanges in developed markets, as classified by BITA GmbH. Under normal circumstances, the fund will invest at least 80% of the fund"s net assets in component securities that make up the index. The fund is non-diversified.